Skip to main content
PLOS One logoLink to PLOS One
. 2026 Jun 2;21(6):e0350385. doi: 10.1371/journal.pone.0350385

The role and targeting potential analysis of angiogenesis-related target THY1 in DSS-induced acute colitis in mice

Pengliang Zhang 1, Xianmin Liu 1, Shuang Chen 2, Yingjian Zhang 1,*
Editor: Subhasis Barik3
PMCID: PMC13229366  PMID: 42228713

Abstract

Background

Immune-driven inflammatory angiogenesis plays a crucial role in the pathogenesis of inflammatory bowel disease (IBD). However, the mechanism of chronic inflammation mediated by angiogenesis still remains unclear. This study aimed to investigate the crucial role and specific mechanism of the angiogenesis-related target THY1 in the development of acute colitis induced by dextran sulfate sodium (DSS) in mice.

Methods

Lentivirus-based systems were utilized to achieve both knockdown and overexpression of THY1 to explore the functional roles of THY1 in IBD development based on DSS-induced colitis mice model and co-culture system of intestinal epithelial cells and macrophages.

Results

THY1 significantly promotes DSS-induced colitis in the experimental mouse model. Silencing of the THY1 significantly reversed the inflammatory response, oxidative stress level, and angiogenic activity in DSS-induced colitis, whereas overexpression of THY1 further exacerbating the reactions related to inflammation, oxidative stress, and angiogenesis. Mechanism research showed that THY1 promotes the pathological process of DSS-induced colitis through inhibiting M2 macrophage polarization. In addition, THY1 promotes apoptosis through the Bcl-2/Bax/Cleaved caspase-3 pathway and promotes angiogenesis via upregulation of HIF-1α and VEGF expression in DSS-induced colitis.

Conclusions

THY1 promotes the occurrence and development of acute colitis induced by DSS in mice by regulating macrophage polarization, intestinal epithelial cell apoptosis, and inflammatory angiogenesis, providing a new perspective for the study of the pathogenesis of IBD. Furthermore, THY1 is expected to become a potential target molecule for the treatment of IBD.

Introduction

Inflammatory Bowel Disease (IBD), including Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a group of diseases characterized by chronic and recurrent gastrointestinal inflammation [1–3]. Its pathogenesis is complex, involving the interaction of multiple factors such as genetic susceptibility, immune dysregulation, gut microbiota disorder, and environmental factors [4,5]. Although the application of biological agents and small-molecule targeted drugs has significantly improved the clinical prognosis of IBD patients in recent years, some patients still have poor treatment responses or develop complications [6]. Therefore, the exploration of novel treatment strategies has become an issue of particular urgency.

Increasing research evidence suggests that immune-driven inflammatory angiogenesis plays a crucial role in the occurrence and development of IBD [7–9]. Under normal physiological conditions, the intestinal vascular network maintains tissue oxygen supply and nutrient exchange through precise regulation, ensuring the stable operation of intestinal functions [10,11]. During the mucosal healing process in the initial stage of IBD, angiogenesis provides indispensable support for tissue repair. It not only promotes the delivery of nutrients but also accelerates the clearance of cellular metabolic waste [12]. However, the inflamed mucosa releases a large number of inflammatory factors, which often lead to tissue damage and further trigger pathological angiogenesis [13]. In addition, the overexpression of pro-angiogenic factors (such as VEGF and TNF-α) drives abnormal blood vessel proliferation, leading to a series of pathological changes such as increased vascular permeability and blood flow disorders [14]. These changes not only further exacerbate tissue hypoxia and inflammatory cell infiltration but may also promote the fibrotic process, thereby increasing the disease burden. Nevertheless, the specific regulatory mechanism of angiogenesis-mediated chronic intestinal inflammation has not been fully elucidated. Whether targeting angiogenesis can become an effective strategy for treating IBD still requires more systematic and in-depth research to clarify its potential clinical value [15]. Exploration in this field not only helps to uncover the complex pathological mechanisms of IBD but may also provide new ideas and directions for future treatment regimens.

Thymocyte antigen-1 (THY1), also known as CD90, is a cell surface protein (25–37 kDa) that anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, which plays an important role in physiological and pathological processes such as tumor angiogenesis, tissue repair, and immune regulation [16,17]. For instance, Foygel et al. have successfully identified and validated THY1 as a specific biomarker for neoangiogenesis in pancreatic ductal adenocarcinoma, which can be effectively detected through ultrasound molecular imaging, thereby enhancing the diagnostic accuracy of this malignancy and contributing to improved patient management [18]. In addition, Single-cell transcriptomics studies have revealed that THY1 ⁺ fibroblasts play a pivotal role as key mediators in driving joint inflammation in rheumatoid arthritis [19,20]. These findings underscore their critical importance in the development of cell-based therapies aimed at modulating inflammation and mitigating tissue damage. Nevertheless, as of the current state of research, the specific role of THY1 in IBD remains unexplored. Furthermore, its potential regulatory mechanisms, particularly its involvement in the pathogenesis of IBD through the modulation of inflammatory angiogenesis and related pathological processes, remain unclear and warrant further investigation. This study aims to explore the potential role of THY1 in the pathological mechanism of IBD from the perspective of HIF-1α/VEGF meditated angiogenesis.

Materials and methods

Animal model construction

Female C57BL/6 mice, aged 8 weeks (weighing 20–22 g), were procured from Vital River Laboratory Animal Technology Co., Ltd. Located in Beijing, China. The mice were adaptively maintained in standard cages (330 × 210 × 170 mm; 6 mice/cage) for 1 week under standardized housing conditions, which included a controlled ambient temperature of 23 ± 2°C, a relative humidity of 55 ± 5%, and a 12-hour light/dark cycle. And the mice were provided unrestricted access to food and water throughout the study. Thirty-six mice in this study were randomly divided into 6 groups (six mice per group): the Sham (blank control) group, the IBD model group, the IBD + OE-THY1 group, the IBD + OE-NC group. the IBD + KD-THY1 group, and the IBD + sh-NC group. Group randomization was performed using a random number table. The sample size was calculated based on a power analysis combining preliminary data and literature benchmarks.

On the 4th day of the adaptive housing period, intraperitoneal injections were given to the mice in each THY1 regulation group. Lentiviral vectors for THY1 overexpression or inhibition (100 μL, containing approximately 5 × 10⁸ PFU) were administered respectively, and the virus titer was adjusted in advance to ensure the consistency of the experiment. The control groups were injected with an equal volume of normal saline (NS) or the corresponding empty vector of the lentivirus. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. After completing the 1 – week adaptive housing (including virus intervention), the drinking water of the mice was replaced with purified water containing 2.5% (w/v) dextran sulfate sodium (DSS) for 7 consecutive days to induce an inflammatory bowel disease (IBD) model. Subsequently, normal drinking water was restored, and the mice were continuously observed until the 10th day of the experiment. During this period, all the mice were maintained in standard cages under standardized housing conditions and provided unrestricted access to food and water. The body weight changes of all mice were recorded daily (from the 1st day to the 10th day of model establishment) to evaluate the disease progression and the effectiveness of model establishment.

Euthanasia will only be carried out before the planned endpoint when the animals meet the pre-defined humane standards. These standards include (but are not limited to): severe weight loss (more than 20% of the baseline body weight) or stunted growth; irreversible signs of pain or suffering (such as shortness of breath, prolonged immobility, inability to access food/water); unexpected complications directly related to the experimental intervention (such as neurological deficits). In this study, no animals needed to be euthanized prematurely because the health indicators of all subjects remained within the pre-set thresholds throughout the experiment. At the end of the experiment, all the mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital (50 mg/kg) and then sacrificed by cervical dislocation, which took about 10 seconds. Peripheral blood and colon tissues were collected for subsequent analysis. Since the experiment was designed as a terminal experiment, no animals were retained after the study. All experimental protocols involving animals were reviewed and approved by the Committee for Animal Care and Use of The First Affiliated Hospital of Henan University of Science & Technology (Approval No. D-2025-B034) and conducted in accordance with the National Laboratory Animal Care and Maintenance Guide.

Histological analysis

H&E staining: Colon tissues were continuously fixed in 40% formaldehyde for 24 hours. They were dehydrated with ethanol, cleared with xylene, embedded in paraffin, and sectioned using a microtome. Paraffin sections of colon tissues were continuously stained with hematoxylin-eosin (H&E), and the tissue damage was observed under an optical microscope.

TUNEL staining: Tissue sections were first treated with xylene to complete the dewaxing step, and then further dewaxed with gradient alcohol to ensure the full preparation of tissue samples. Next, antigen retrieval is performed using citrate buffer to restore the antigen activity in the tissue. To reduce non – specific binding, the sections are blocked with 5% skimmed milk powder. On this basis, the TdT enzyme reaction solution and the streptavidin – fluorescein isothiocyanate (Streptavidin – FITC) labeled working solution are successively applied to the tissue sections, and the TUNEL staining operation is completed according to the standard procedure.

Cell culture and establishment of the colitis cell model

Normal human intestinal epithelial cell line NCM460 were acquired from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in DMEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco, Waltham, MA, USA) and 100 units of penicillin/streptomycin, and then placed in a constant-temperature incubator at 37°C with 5% CO₂ for growth. NCM460 cells were gradient intervention with different concentrations of DSS (e.g., 0, 0.1, 0.2, 0.5, 1, 2 μg/mL) for 12 hours to establish an IBD cell model. The cells and its supernatant were collected and stored at −80 °C for subsequent ELISA, RT-qPCR and Western blotting (WB) assay. The expression levels of inflammatory factors including IL-1β, IL-6, TNF-α, and TGF-β in cells and its supernatant were detected by ELISA to evaluate the disease progression and the effectiveness of model establishment, referring to the published methods [21]. After verifying its inflammation-inducing efficiency on NCM460 cells, a DSS working concentration of 1 μg/ml was selected for the subsequent cell experiments (S1 Fig).

Cell transfection

The shRNA targeting THY1 (sh-THY1) and the THY1-overexpressing plasmid (pcDNA3.1-THY1), along with their corresponding control constructs, were obtained from GenePharma (Shanghai, China). NCM460 cells were transfected with these constructs using Lipofectamine 2000 (Invitrogen) for a duration of 48 hours, following the manufacturer’s recommended protocol. The efficiency of both knockdown and overexpression was subsequently evaluated through qRT-PCR and Western blot analyses.

Establishment of co-culture system

In this study, a co-culture system of intestinal epithelial cells and macrophages was established using the Transwell chamber system. The specific operations are as follows: untreated NCM460 cells or successfully transfected NCM460 cells were seeded in the lower layer of the Transwell chamber at a density of 1 × 10⁵ cells/well, while 0.5 × 10⁵ THP-1 cells that had been induced and differentiated by Phorbol 12-myristate 13-acetate (PMA, 100 ng/ml) for 24 hours were added to the upper layer. Subsequently, DMEM complete medium was added to the system, and DSS with a final concentration of 1 μg/ml was added for 12 hours of culture. After the intervention, the cells and its supernatant from the upper and lower layers of the chamber were collected respectively, and samples were stored at −80 °C for subsequent ELISA, RT-qPCR, Western blotting (WB) and Flow cytometry assays. The co-culture system was divided into 6 groups: Blank group (Upper layer: empty; Lower layer: normal NCM460 cells), Control group (Upper layer: THP-1 cells; Lower layer: normal NCM460 cells), sh-THY1 group (Upper layer: THP-1 cells; Lower layer: sh-THY1 treated NCM460 cells), sh-NC group (Upper layer: THP-1 cells; Lower layer: sh-NC treated NCM460 cells), OE-THY1 group (Upper layer: THP-1 cells; Lower layer: OE-THY1 treated NCM460 cells), and OE-NC group (Upper layer: THP-1 cells; Lower layer: OE-NC treated NCM460 cells).

Enzyme-linked immunosorbent assay (ELISA)

Pro-inflammatory cytokines (IL-1β, TNF-α, and TGF-β), oxidative stress-related molecules (ROS, MDA and GSH) and angiogenesis-related stimulatory factors (HIF-1 and VEGF) were quantified utilizing the respective ELISA kits (mlbio, Shanghai, China) following the manufacturer’s instruction. In short, the samples including mouse colon tissue, mouse serum, cells and its supernatant samples were treated with the reaction solution and termination solution. The absorbance was assessed at a wavelength of 450 nm utilizing a microplate reader (Molecular Devices).

Quantitative real-time PCR

Total RNA was isolated from cells using TRIzol reagent (Invitrogen). The extracted RNA was reverse transcribed into cDNA using PrimeScript RT Reagent kit (Takara, Dalian, China). Quantitative real-time PCR was conducted with SYBR Premix Ex Taq kit (Takara) on the ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) with specific primers according to the manufacturer’s instructions. Gene expression was calculated utilizing 2-∆∆Ct method as normalized to GAPDH. Primers used in this study were synthesized by Shanghai Sangon Biotechnology Co., Ltd. (Shanghai, China) and primer sequences are shown in Table 1.

Table 1. The primer sequences for relative mRNA used in this study.

Primer name Sequence (5’-3’)
THY1-human-F ATCGCTCTCCTGCTAACAGTC
THY1-human-R CTCGTACTGGATGGGTGAACT
β-actin-human-F ACGTGGACATCCGCAAAG
β-actin-human-R TGGAAGGTGGACAGCGAGGC
THY1-mouse-F GCTCTCAGTCTTGCAGGTGTC
THY1-mouse-R CAGGCGAAGGTTTTGGTTCA
VEGF-mouse-F GCTACTGCCGTCCGATTGAGA
VEGF-mouse-R GCTGGCTTTGGTGAGGTTTGAT
HIF-1α-mouse-F GATGACGGCGACATGGTTTAC
HIF-1α-mouse-R CTCACTGGGCCATTTCTGTGT
β-actin-mouse-F GTGACGTTGACATCCGTAAAGA
β-actin-mouse-R GCCGGACTCATCGTACTCC

Western blot

Following the application of the respective treatments, cellular proteins were extracted from each sample by the Radio-Immunoprecipitation Assay (RIPA) lysis buffer (Beyotime Biotechnology, Shanghai, China). Protein concentrations were determined using the BCA (bicinchoninic acid) protein assay kit (Beyotime). Subsequently, the proteins were fractionated on SDS-PAGE gels containing either 10% or 12% acrylamide and then electrophoretically transferred onto PVDF membranes. The membranes were blocked with 5% BSA and subsequently probed with immunoblotting techniques. Primary antibodies like anti-THY1 (14-0909-82, 0.5 mg/mL; Thermo Fisher), anti-Bcl-2 (12789–1-AP, 1:2000; Proteintech), anti-Bax (50599–2-Ig, 1:5000; Proteintech), anti-cleaved caspase-3 (abs132005, 1:500; Absin), anti-HIF-1α (BF8002, 1:1000; Affinity) and anti-VEGF (ab46154, 1:1000; Abcam) were used at the indicated dilutions and incubated at 4°C. After the membrane was washed three times, the secondary antibody goat Anti-Human IgG Fc (HRP) (ab98624, 1:5000; Abcam), was incubated at room temperature for 2 hours. The membrane was scanned and imaged using the ChemiDoc XRS+ imaging system (Bio-Rad, America) after color development with ECL chemiluminescent reagent (Beyotime). For image quantification, the immunoblots were analyzed using ImageJ software and the protein levels were quantified as the ratio of its gray value to that of β-actin (GB11001, 1:2000; Serivicebio).

Flow cytometry analysis

Macrophage immunophenotyping: the upper THP-1 cells from co-culture system were collected, washed and resuspended in PBS. Then, 5 µL of CD11b-FITC, CD86-APC (M1 marker) or CD206-APC (M2 marker) were added and incubate at room temperature in the dark for 15 min. Subsequently, the M1 or M2 macrophages were enumerated using a FACS Canto II flow cytometer. The gating strategy adopted a step-by-step approach: First, use the forward scatter (FSC)/side scatter (SSC) parameters to exclude debris and doublet cells, and then select live CD11b+ monocytes/macrophages.

Apoptosis of NCM460 cells in co-culture system was assayed using the Annexin V-FITC apoptosis detection kit provided by BD Biosciences. Cells were harvested, rinsed with PBS, and resuspended in 300 microliters of Annexin V binding buffer to achieve a single-cell suspension. Next, 5 microliters of Annexin-V-fluorescein isothiocyanate (FITC) and 5 microliters of propidium iodide (PI) were concurrently added to the cell suspension and incubated in the dark at ambient temperature for a period of 15 minutes. Subsequently, the apoptotic cells were enumerated using a FACS Canto II flow cytometer.

In vitro tube formation assay

The 96-well plates were pre-coated with a frozen Matrigel solution (phenol red-free type; BD Biosciences, New Jersey, USA) and incubated at 37°C for at least 30 minutes to ensure full solidification of the Matrigel. Subsequently, human umbilical vein endothelial cells (HUVECs) were collected and suspended in a low-serum medium containing 2% fetal bovine serum (FBS), then seeded into the Matrigel-coated wells at a density of 1 × 10⁵ cells/ml per well and pre-incubated at 37°C for 30 minutes to allow cell attachment. During this process, the cell culture supernatants previously collected from different experimental groups in the co-culture system were used as conditioned media for HUVECs and placed in the cell incubator for further incubation. Images of the formed tubular structures were acquired using a real-time cell imager (NanoEntek, Seoul, South Korea) during the 4–24 hours of regular cell culture.

Statistical analyses

Statistical evaluations were performed utilizing the GraphPad Prism 8 software package. Unless indicated otherwise, the data presented are expressed as the mean ± SD, derived from a minimum of three separate experiments. Significance testing of the differences between means was conducted using either two-tailed Student’s t-tests or ANOVA, with subsequent application of Tukey’s post hoc test, as deemed appropriate for the specific dataset.

Results

THY1 promotes dextran sulfate sodium (DSS)-induced colitis in mice

In this study, lentivirus-based systems were utilized to achieve both knockdown and overexpression of THY1 to explore the functional roles of THY1 in IBD development. Following the stable transfection of NCM460 cells with THY1 suppression and overexpression vectors, the successful knockdown and overexpression of THY1 expression levels was both confirmed and visually demonstrated (Fig 1A). In DSS-induced colitis mouse model, the administration of 3.0% DSS induced an increased expression of THY1 compared to the control group, and successful knockdown and overexpression of THY1 expression levels were also confirmed and visualized following lentivirus injection via the tail vein with sh-THY1 and OE-THY1 (Fig 1B). As illustrated in Fig 1C and 1D, the administration of 3.0% DSS over a period of 10 days resulted in significant weight loss and a marked reduction in colon length compared to the control group, whereas knockdown of THY1 effectively alleviated these adverse effects while overexpression of THY1 significantly aggravated the symptoms of enteritis. In addition, histological examination of colon sections showed that the samples from mice treated with DSS + sh-THY1 exhibited well-preserved colon structure, no obvious ulcers, and reduced inflammatory cell infiltration in contrast to that observed in DSS and DSS + sh-NC groups, while the samples from mice treated with DSS + OE-THY1 showed further damaged colon structure with obvious ulcers and an increase in inflammatory cell infiltration compared to DSS and DSS + OE-NC groups (Fig 1E). These findings collectively demonstrate that THY1 significantly promotes DSS-induced colitis in the experimental mouse model.

Fig 1. THY1 promotes dextran sulfate sodium (DSS)-induced colitis in mice.

Fig 1

(A, B) The knockdown and overexpression of THY1 expression levels in NCM460 cells and DSS-induced colitis mouse colon tissue samples were determined by quantitative real-time PCR and western blot analysis, respectively. (C) Body weight loss and (D) Appearance of colon length of DSS-induced colitis mouse in different treatment groups including the Sham (blank control) group, the IBD model group, the IBD + OE-THY1 group, the IBD + OE-NC group. the IBD + KD-THY1 group, and the IBD + sh-NC group. (E) Representative H&E staining images of DSS-induced colitis mouse colon samples in different treatment groups. The corresponding image below is a high-magnification view of the red square position in the image above. A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

THY1 promotes the pathological process of DSS-induced colitis and inhibits M2 macrophage polarization

In order to deeply explore the specific mechanism by which THY1 plays a role in DSS-induced colitis, this study conducted multi-level analyses on mouse peripheral blood and colon tissue samples. First, the expression levels of inflammatory factors, oxidative stress-related molecules and angiogenesis-related stimulatory factors were systematically detected to evaluate their dynamic changes during the pathological process. Compared with the control group, the expression of inflammatory factors IL-1β and TNF-α was significantly upregulated in the DSS treatment group, while the expression of TGF-β was significantly downregulated. Meanwhile, the levels of molecules related to oxidative stress, ROS and MDA, were significantly increased, while the level of the antioxidant molecule GSH was significantly decreased. In addition, the expression of key stimulatory factors related to angiogenesis, HIF-1 and VEGF, also showed a significant upward trend (Figs 2A and S2). These results indicate that there are obvious inflammatory responses, enhanced oxidative stress, and increased angiogenic activity in the DSS-induced colitis model. Further studies found that silencing of the THY1 could significantly reverse the inflammatory response, oxidative stress level, and angiogenic activity in DSS-induced colitis. In contrast, overexpression of THY1 showed the opposite effect, further exacerbating the reactions related to inflammation, oxidative stress, and angiogenesis (Figs 2A and S2). These results suggest that THY1 may play an important regulatory role in the pathological process of DSS-induced colitis.

Fig 2. THY1 promotes the pathological process of DSS-induced colitis.

Fig 2

(A, B) The expression levels of inflammatory factors (IL-1β, TNF-α and TGF-β), oxidative stress-related molecules (ROS, MDA and GSH) and angiogenesis-related stimulatory factors (HIF-1α and VEGF) in mouse colon tissue samples and NCM460 cell homogenate of co-culture system were detected by enzyme-linked immunosorbent assay (ELISA). A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001‌‌.

In addition, we successfully established a co-culture system of macrophages and intestinal epithelial cells utilizing Transwell chambers to further validate the regulatory role of THY1 in the pathological progression of DSS-induced colitis. As shown in Fig 2B, co-culturing with macrophages (Control group) significantly upregulated the expression of inflammatory factors (IL-1β and TNF-α), and at the same time significantly inhibited the level of the anti-inflammatory factor (TGF-β) in NCM460 cell homogenates compared with Blank group. In addition, significant changes also occurred in molecules related to oxidative stress: the levels of ROS (reactive oxygen species) and MDA (malondialdehyde) increased significantly, while the content of GSH (glutathione) decreased significantly. Meanwhile, the expression of key factors related to angiogenesis, HIF-1 and VEGF, also increased significantly. It is worth noting that the expression regulation of the THY1 on colonocytes has an important impact on the above reactions. When THY1 on colonocytes was silenced, the DSS-induced inflammation, oxidative stress, and angiogenesis reactions were significantly reversed in co-culture system, manifested as the downregulation of inflammatory factors and oxidative stress markers, as well as the restoration of anti-inflammatory and antioxidant molecules. In contrast, the overexpression of THY1 on colonocytes exacerbated these pathological reactions and further promoted the abnormal expression of factors related to inflammation, oxidative stress, and angiogenesis. These results were highly consistent with our previous findings in the in vivo colitis mouse model, further verifying the reliability of this in vitro model. To further explore the specific mechanism of THY1 in the pathological process of DSS-induced colitis, macrophage immunophenotyping were evaluated by flow cytometry. Results showed that silencing of the THY1 on colonocytes significantly induced M2 macrophage polarization while overexpression of THY1 on colonocytes significantly inhibited M2 macrophage polarization (Fig 3). Taken together, these results suggested that THY1 promotes the pathological process of DSS-induced colitis by inhibiting M2 macrophage polarization. Experimentally deplete macrophages or alter macrophage phenotypic states under THY1-OE or THY1-silenced conditions are still needed to establish such causal connection.

Fig 3. THY1 inhibits M2 macrophage polarization.

Fig 3

(A, B) Macrophage immunophenotyping (M1 polarization and M2 polarization) were evaluated by flow cytometry in co-culture system of control group (Upper layer: THP-1 cells; Lower layer: normal NCM460 cells), sh-THY1 group (Upper layer: THP-1 cells; Lower layer: sh-THY1 treated NCM460 cells), sh-NC group (Upper layer: THP-1 cells; Lower layer: sh-NC treated NCM460 cells), OE-THY1 group (Upper layer: THP-1 cells; Lower layer: OE-THY1 treated NCM460 cells), and OE-NC group (Upper layer: THP-1 cells; Lower layer: OE-NC treated NCM460 cells). A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

THY1 promotes apoptosis in the colonic tissue of mice with DSS-induced colitis through the Bcl-2/Bax/Cleaved caspase-3 pathway

The TUNEL staining technique was used to further investigate the cell apoptosis in colon tissues, thus providing experimental evidence for revealing the key nodes regulated by THY1. TUNEL staining results showed that, compared with the control group, significant cell apoptosis occurred in the colon tissues of the DSS-treated group. Knocking down THY1 could significantly reduce the degree of tissue apoptosis. On the contrary, overexpression of THY1 further exacerbated tissue apoptosis (Fig 4A). This result indicates that THY1 plays an important role in regulating the apoptosis process of colon tissue cells. To further verify the above findings, we detected the expression levels of pro-apoptotic proteins Bax and caspase-3 and anti-apoptotic protein Bcl-2 by Western blot analysis. The results showed that knocking down THY1 could significantly down-regulate the expression of pro-apoptotic proteins Bax and cleaved caspase3, and at the same time up-regulate the expression of anti-apoptotic protein Bcl-2. In contrast, overexpression of THY1 further enhanced the expression of Bax and cleaved caspase-3 and inhibited the expression of Bcl-2, which showed a significant difference from the results of the DSS-treated group (Fig 4B).

Fig 4. THY1 promotes apoptosis in DSS-induced colitis through the Bax/cleaved caspase3/Bcl-2 pathway.

Fig 4

(A) Representative TUNEL staining images of DSS-induced colitis mouse in the Sham (blank control) group, the IBD model group, the IBD + OE-THY1 group, the IBD + OE-NC group. the IBD + KD-THY1 group, and the IBD + sh-NC group. (B) The expression levels of apoptosis-related proteins (Bax, Bcl-2 and cleaved caspase3) in DSS-induced colitis mouse colon tissue samples of the Sham (blank control) group, the IBD model group, the IBD + OE-THY1 group, the IBD + OE-NC group. the IBD + KD-THY1 group, and the IBD + sh-NC group. A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Furthermore, the in vitro co-culture system of macrophages and intestinal epithelial cells further confirmed that compared with the Control group, interfering with the expression of THY1 could reduce the apoptosis of intestinal epithelial cells by inhibiting the expression of pro-apoptotic proteins Bax and cleaved caspase-3 and promoting the expression of anti – apoptotic protein Bcl-2. Conversely, overexpression of THY1 further exacerbated their apoptotic response of intestinal epithelial cells (Fig 5A and 5B). These data together reveal the molecular mechanism by which THY1 participates in the apoptosis of colon tissue cells by regulating the expression of apoptosis-related proteins.

Fig 5. THY1 promotes apoptosis in intestinal epithelial cells through the Bax/cleaved caspase3/Bcl-2 pathway.

Fig 5

(A) Apoptosis level and (B) apoptosis-related proteins (Bax, Bcl-2 and cleaved caspase3) expression levels of NCM460 cells in co-culture system of different treatment groups were determined by flow cytometry and western blot analysis, respectively. A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

THY1 promotes angiogenesis via upregulation of HIF-1α and VEGF expression in IBD

HE staining showed that the thickness of the blood vessel wall was significantly increased in DSS-induced colitis mouse model. However, knockdown of THY1 significantly decreased the thickness of the blood vessel wall while overexpression of THY1 further increased the thickness of the blood vessel wall, indicating the regulatory effect of THY1 on the structural changes of blood vessels (Fig 6A). Quantitative real-time PCR and Western blot analysis of the mouse colon tissue samples illustrated that knockdown of THY1significantly downregulated the expression of key stimulatory factors related to angiogenesis, HIF-1α and VEGF. In contrast, overexpression of THY1 further upregulated the expression of HIF-1α and VEGF, which was in sharp contrast to the DSS group (Fig 6B and 6C).

Fig 6. THY1 promotes angiogenesis via upregulation of HIF-1α and VEGF expression in IBD.

Fig 6

(A) Representative H&E staining images of DSS-induced colitis mouse colon samples revealed the growth and thickness of the blood vessel wall in different treatment groups. The red square position in the image revealed the blood vessel. (B) The mRNA expression levels and (C) protein expression levels of HIF-1α and VEGF in DSS-induced colitis mouse colon tissue samples determined by quantitative real-time PCR and western blot analysis, respectively. (D) The in vitro angiogenic capacity of HUVECs stimulated with the cell culture supernatants collected from different treatment groups. (E) The protein expression levels of HIF-1α and VEGF in NCM460 cells in co-culture system of different treatment groups were determined by western blot analysis. A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

To further verify the above findings, we evaluated the role of THY1 in inflammatory angiogenesis by performing a tube formation assay based on human umbilical vein endothelial cells (HUVECs) using cell culture supernatants. The experimental results showed that, compared with the blank control (culture medium) group, the supernatants of DSS-treated NCM460 cells and the co-culture supernatants of NCM460 cells and macrophages significantly promoted the tube formation of HUVECs (Fig 6D). However, when the supernatants of THY1-knockdown NCM460 cells were used, the tube formation ability of HUVECs was significantly inhibited. In contrast, the supernatants of THY1-overexpressing NCM460 cells showed a strong pro-tube formation effect, further confirming the crucial role of THY1 in regulating angiogenesis. Notably, western blot analysis of cell samples also illustrated that knockdown of THY1significantly downregulated the expression of key stimulatory factors related to angiogenesis, HIF-1α and VEGF (Fig 6E). In contrast, overexpression of THY1 further upregulated the expression of HIF-1α and VEGF, which was in sharp contrast to the DSS group. These results together suggest that THY1 promotes angiogenesis via upregulation of HIF-1α and VEGF expression in IBD.

Discussion

Currently, targeted therapies focusing on specific inflammatory factors and their signaling pathways, such as ustekinumab targeting IL-12 and IL-23 and small-molecule drugs tofacitinib and upadacitinib targeting the janus kinase (JAK) pathway, have provided new treatment options for patients with IBD [22,23]. However, although biologic targeted therapy shows significant efficacy in many patients, approximately 30% of patients do not respond to the initial treatment, and up to 50% of patients may gradually lose their treatment response over time [24]. This situation highlights the importance of further exploring potential therapeutic targets for IBD. Future research should focus on blocking the signaling pathways related to key inflammatory factors to effectively control intestinal inflammation, promote mucosal healing, and thus improve the intestinal and extra – intestinal manifestations of IBD. In this study, we revealed the crucial role of the angiogenesis-related target THY1 in the development of acute colitis induced by dextran sulfate sodium (DSS) in mice. Through in vivo and in vitro experiments, we confirmed that THY1 promotes pathological angiogenesis by regulating the HIF-1α/VEGF signaling pathway and induces apoptosis through the Bcl-2/Bax/Cleaved caspase-3 pathway, further exacerbates the pathological process of DSS-induced colitis via inhibiting M2 macrophage polarization. These findings not only deepen our understanding of the pathogenesis of IBD but also provide important theoretical basis for the development of novel treatment strategies.

Inflammatory bowel disease (IBD) is a non-specific inflammatory disease closely related to the imbalance of the body’s immune system [25]. In this complex pathological process, macrophages, as key immune regulators, play a dual role: they are not only important phagocytes for phagocytosing and digesting pathogens but also play an indispensable role in maintaining the homeostasis of the intestinal microenvironment [26]. From a pathophysiological perspective, macrophages directly participate in and promote the occurrence and development of the inflammatory response by releasing a variety of inflammatory mediators (such as TNF – α, IL – 1β, etc.) [27]. However, the relationship between macrophages and IBD is not a simple linear causal relationship but presents a complex interactive model of dynamic balance. On the one hand, macrophages can exacerbate the pathological process of IBD by secreting pro-inflammatory factors; on the other hand, they can also inhibit the development of the disease by regulating the immune response [28]. For example, macrophages can release anti-inflammatory mediators (such as IL-10), thereby effectively inhibiting excessive inflammatory responses and protecting intestinal tissues from further damage [29]. This dual role indicates that macrophages are both “drivers” of inflammation and potential “guardians,” and their specific functions may depend on signal regulation in the microenvironment and cell to cell interactions. Our research results show that DSS stimulation inhibits the M2 polarization of macrophages, leading to the release of pro-inflammatory factors such as TNF-α and IL-1β, which act on intestinal epithelial cells and promote cell apoptosis [30]. Notably, in vitro co-culture experiments have confirmed that interfering with the expression of THY1 promotes the M2 polarization of THP-1 cells and down-regulates the secretion of pro-inflammatory factors such as TNF-α and IL-1β, while overexpressing THY1 further inhibits the M2 polarization of THP-1 cells and promotes the secretion of pro – inflammatory factors such as TNF-α and IL-1β. All these studies indicate that THY1 plays a key role in the pathogenesis of IBD by inhibiting the polarization of M2 macrophages.

In addition, damage to the intestinal epithelial cell barrier function serves as one of the critical initiating factors in the pathogenesis of IBD. Among the various mechanisms implicated, abnormal apoptosis of intestinal epithelial cells has been identified as a pivotal driver of mucosal integrity disruption [31]. The findings of this study demonstrate that THY1 can promote intestinal epithelial cell apoptosis by modulating the Bcl-2/Bax/Cleaved caspase-3 signaling pathway. Specifically, the upregulation of Bax, a pro-apoptotic protein, coupled with the downregulation of Bcl-2, an anti-apoptotic protein, synergistically facilitates the cleavage and activation of caspase-3. This cascade ultimately exacerbates the death of intestinal epithelial cells. The intervention targeting THY1 was shown to refine the regulatory mechanisms governing intestinal epithelial cell apoptosis. This suggests that the targeted inhibition of THY1 may represent a promising therapeutic strategy to decelerate colitis progression by preserving the functional integrity of the intestinal epithelial barrier. Furthermore, the HIF-1α/VEGF axis serves as the pivotal regulatory pathway in angiogenesis. Its abnormal activation can result in increased intestinal vascular density, thereby providing nutritional support for the infiltration of inflammatory cells and exacerbating the inflammatory response [32]. This study reveals that THY1 can promote intestinal angiogenesis by upregulating the expression of HIF-1α and VEGF. These findings elucidate the upstream regulatory role of THY1 in inflammatory angiogenesis and offer a novel strategy for interrupting the “inflammation-angiogenesis” vicious cycle in IBD.

Nevertheless, this study is subject to several limitations. To begin with, the biological functions of THY1 were investigated based on mice and cell models, and its specific role in IBD still needs to be verified using human clinical samples. Secondly, the molecular interaction mechanism by which THY1 mediates angiogenesis and affects colitis remains to be fully elucidated, necessitating further investigation in future research.

Conclusions

In conclusion, this study demonstrates that THY1 promotes the progression of DSS-induced acute colitis in mice by regulating macrophage polarization, intestinal epithelial cell apoptosis, and inflammatory angiogenesis, which provides a new perspective for the study of the pathogenesis of IBD and offers important experimental evidence for the development of clinical targeted treatment strategies. Future research can further explore the specific molecular mechanism of THY1 regulation and its application prospects in clinical translation.

Transparent reporting on AI and AI-assisted Technologies

During the preparation of this work the authors used the AI translation function of Tianxi Personal Super Intelligent Agent (Version number: 3.5.0.10302, Lenovo Group) in order to improve the English language of the article. For example, enhance the academic tone to make the English expression clearer and more professional, and in line with the style of academic writing‌‌.

Supporting information

S1 Fig. Evaluation of the effectiveness of cell model establishment.

The expression levels of inflammatory factors including IL-1β, IL-6, TNF-α, and TGF-β in NCM460 cells (A) and its supernatant (B) were detected by ELISA. NCM460 cells were gradient intervention with different concentrations of DSS (e.g., 0, 0.1, 0.2, 0.5, 1, 2 μg/mL) for 12 hours. A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

(TIF)

pone.0350385.s001.tif (1.3MB, tif)
S2 Fig. THY1 promotes the pathological process of DSS-induced colitis.

The expression levels of inflammatory factors (IL-1β, TNF-α and TGF-β), oxidative stress-related molecules (ROS, MDA and GSH) and angiogenesis-related stimulatory factors (HIF-1α and VEGF) in mouse blood serum samples of different treatment groups were detected by enzyme-linked immunosorbent assay (ELISA). A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

(TIF)

pone.0350385.s002.tif (4.2MB, tif)
S3 Fig. The full uncropped Gels and Blots images used in this study.

(PDF)

pone.0350385.s003.pdf (284.7KB, pdf)
S4 Fig. Original data sets for Figures in this study.

(ZIP)

pone.0350385.s004.zip (28.9MB, zip)

Acknowledgments

No additional acknowledgements beyond the listed authors are applicable to this study.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Hodson R. Inflammatory bowel disease. Nature. 2016;540(7634):S97. doi: 10.1038/540S97a [DOI] [PubMed] [Google Scholar]
  • 2.Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi: 10.1038/s41572-020-0205-x [DOI] [PubMed] [Google Scholar]
  • 3.Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22. doi: 10.1038/s41572-020-0156-2 [DOI] [PubMed] [Google Scholar]
  • 4.Kong L, Pokatayev V, Lefkovith A, Carter GT, Creasey EA, Krishna C, et al. The landscape of immune dysregulation in Crohn’s disease revealed through single-cell transcriptomic profiling in the ileum and colon. Immunity. 2023;56(2):444-458.e5. doi: 10.1016/j.immuni.2023.01.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease. United European Gastroenterol J. 2022;10(10):1047–53. doi: 10.1002/ueg2.12319 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Liu J, Di B, Xu L-L. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine Growth Factor Rev. 2023;71–72:1–12. doi: 10.1016/j.cytogfr.2023.07.001 [DOI] [PubMed] [Google Scholar]
  • 7.Wang Y, Bai M, Peng Q, Li L, Tian F, Guo Y, et al. Angiogenesis, a key point in the association of gut microbiota and its metabolites with disease. Eur J Med Res. 2024;29(1):614. doi: 10.1186/s40001-024-02224-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Duan Z-L, Wang Y-J, Lu Z-H, Tian L, Xia Z-Q, Wang K-L, et al. Wumei Wan attenuates angiogenesis and inflammation by modulating RAGE signaling pathway in IBD: Network pharmacology analysis and experimental evidence. Phytomedicine. 2023;111:154658. doi: 10.1016/j.phymed.2023.154658 [DOI] [PubMed] [Google Scholar]
  • 9.Zhou G, Zhang M, Zheng S, Yang G, Li L, Huang S, et al. Transglutaminase 2 modulates inflammatory angiogenesis via vascular endothelial growth factor receptor 2 pathway in inflammatory bowel disease. J Adv Res. 2026;82:751–64. doi: 10.1016/j.jare.2025.07.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wettschureck N, Strilic B, Offermanns S. Passing the Vascular Barrier: Endothelial Signaling Processes Controlling Extravasation. Physiol Rev. 2019;99(3):1467–525. doi: 10.1152/physrev.00037.2018 [DOI] [PubMed] [Google Scholar]
  • 11.Rafii S, Butler JM, Ding B-S. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529(7586):316–25. doi: 10.1038/nature17040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zheng H, Yu J, Gao L, Wang K, Xu Z, Zeng Z, et al. S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity. Nat Commun. 2025;16(1):1826. doi: 10.1038/s41467-025-57124-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Deban L, Correale C, Vetrano S, Malesci A, Danese S. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol. 2008;172(6):1457–66. doi: 10.2353/ajpath.2008.070593 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Li Z, Zeng L, Huang W. Angiogenic factors and inflammatory bowel diseases. Biomedicines. 2025;13(5):1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Binion DG, Rafiee P. Is inflammatory bowel disease a vascular disease? Targeting angiogenesis improves chronic inflammation in inflammatory bowel disease. Gastroenterology. 2009;136(2):400–3. doi: 10.1053/j.gastro.2008.12.029 [DOI] [PubMed] [Google Scholar]
  • 16.Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J. 2006;20(8):1045–54. doi: 10.1096/fj.05-5460rev [DOI] [PubMed] [Google Scholar]
  • 17.Wang L, Hu R, Xu P, Gao P, Mo B, Dong L, et al. CD90’s role in vascularization and healing of rib fractures: insights from Dll4/notch regulation. Inflamm Res. 2024;73(12):2263–77. doi: 10.1007/s00011-024-01962-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Foygel K, Wang H, Machtaler S, Lutz AM, Chen R, Pysz M, et al. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Gastroenterology. 2013;145(4):885-894.e3. doi: 10.1053/j.gastro.2013.06.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Croft AP, Campos J, Jansen K, Turner JD, Marshall J, Attar M, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019;570(7760):246–51. doi: 10.1038/s41586-019-1263-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019;20(7):928–42. doi: 10.1038/s41590-019-0378-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Xiong T, Wang X, Li J, Li F. Predictive value of long non-coding RNA DDX11-AS1 in inflammatory bowel disease and its effect on intestinal mucosal cell function. Cent Eur J Immunol. 2025;50(1):87–97. doi: 10.5114/ceji.2025.149579 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pugliano CL, Liang RF-H, Ruffa A, Iacucci M, Ghosh S. Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters? J Crohns Colitis. 2025;19(8):jjaf144. doi: 10.1093/ecco-jcc/jjaf144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zheng B, Wang L, Yi Y, Yin J, Liang A. Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease. Asian J Pharm Sci. 2024;19(4):100943. doi: 10.1016/j.ajps.2024.100943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Bretto E, Ribaldone DG, Caviglia GP, et al. Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies. Biomedicines. 2023;11(8):2249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Wang J, Tan H, Ye Z, Weng S, Shi Y, Xu J, et al. Gut microbial Nordihydroguaiaretic acid suppresses macrophage pyroptosis to regulate epithelial homeostasis and inflammation. Gut Microbes. 2025;17(1):2518338. doi: 10.1080/19490976.2025.2518338 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.De Schepper S, Verheijden S, Aguilera-Lizarraga J, Viola MF, Boesmans W, Stakenborg N, et al. Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis. Cell. 2019;176(3):676. doi: 10.1016/j.cell.2019.01.010 [DOI] [PubMed] [Google Scholar]
  • 27.Bloemendaal FM, Koelink PJ, van Schie KA, Rispens T, Peters CP, Buskens CJ, et al. TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism. J Crohns Colitis. 2018;12(9):1122–30. doi: 10.1093/ecco-jcc/jjy075 [DOI] [PubMed] [Google Scholar]
  • 28.Zhang K, Guo J, Yan W, Xu L. Macrophage polarization in inflammatory bowel disease. Cell Commun Signal. 2023;21(1):367. doi: 10.1186/s12964-023-01386-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Xiao P, Zhang H, Zhang Y, Zheng M, Liu R, Zhao Y, et al. Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10. J Exp Med. 2019;216(2):337–49. doi: 10.1084/jem.20181198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lin Y, Wang D, Zhao H, Li D, Li X, Lin L. Pou3f1 mediates the effect of Nfatc3 on ulcerative colitis-associated colorectal cancer by regulating inflammation. Cell Mol Biol Lett. 2022;27(1):75. doi: 10.1186/s11658-022-00374-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zhou Z, Miao X, Shen Y, Wang P, Shi R, Fan H, et al. Macrophage extracellular traps impair intestinal barrier function in DSS-induced colitis in mice by inducing intestinal epithelial cell apoptosis. Biochem Pharmacol. 2025;242(Pt 3):117406. doi: 10.1016/j.bcp.2025.117406 [DOI] [PubMed] [Google Scholar]
  • 32.Yuan M, Wu Y, Zhou X, Cai Y, Li H, Xia A, et al. Clematichinenoside AR alleviates rheumatoid arthritis by inhibiting synovial angiogenesis through the HIF-1α/VEGFA/ANG2 axis. Phytomedicine. 2025;139:156552. doi: 10.1016/j.phymed.2025.156552 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Subhasis Barik

10 Mar 2026

-->PONE-D-26-02176-->-->The role and targeting potential analysis of angiogenesis-related target THY1 in DSS-induced acute colitis in mice-->-->PLOS One

Dear Dr. Zhang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Subhasis Barik

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

Both the reviewers raised multiple issues that need to be addressed in the revised manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Partly

Reviewer #2: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: No

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: No

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: The manuscript entitled “The role and targeting potential analysis of angiogenesis-related target THY1 in DSS-

induced acute colitis in mice” explores the role of THY1 in two aspects of DSS-induced colitis: alterations in colonocyte biology and changes in macrophage phenotypes. While the study apparently focuses on how THY1 regulates the phenotypic alterations of these cells that lead to colitis pathology, there are specific points which are not clear to me in terms of logic, as outlined below.

Major points

1- How well-established is the cell line-based model of IBD (lines 159-161)? Authors need to cite references.

2- How could the authors guarantee that the lentiviral vector-mediated delivery of the constructs could solely be targeted to colonocytes and not any stromal or immune cells around them? This is particularly important as THY1 expression on stromal cells has a crucial role in colitis pathogenesis (reference: https://doi.org/10.4049/jimmunol.212.supp.1326.5032).

3- The 2nd point of the results (lines 303-348) only shows that THY1 causes definite changes in macrophage phenotypes parallel to the aggravation of DSS-induced colitis in mice. How could the authors draw a causal inference in the statement “THY1 promotes the pathological process of DSS-induced colitis through inhibiting M2 macrophage polarization?” To establish such causal connection, authors need to experimentally deplete macrophages or alter macrophage phenotypic states under THY1-OE or THY1-silenced conditions, and repeat the same experiments in vivo.

4- In the same point, the authors seemingly check several different aspects (cytokines, ROS, angiogenesis markers) related to macrophages. However, there is no definitive proof that the changes in these markers due to THY1 manipulations are solely, or at least majorly, related to their altered output from macrophages in vivo. In addition, why they check so many aspects together without any apparently clear hypothesis is not understandable.

5- Again, in the coming sections, authors assess colonocyte apoptosis and angiogenesis marker levels without any clear connection to the previous sections. The entire story looks like an ensemble of experiments without any proper logical link among them.

6- Although the authors check multiple phenotypic effects of THY1 manipulations on colonocytes, how each of them affects colitis has not been checked. So the entire set of findings by large stays correlative.

7- Why do the authors check ROS-related phenotypes (ROS, MDA, GSH etc) in cell supernatants? It would have been more physiologically relevant if they had done the experiment with cell homogenates/lysates.

8- None of the experiments involve DSS-conditioning of the THP-1 cells, and only involves co-culturing them with colonocytes of different phenotypes. This violates the physiology of colitis, where macrophages also encounter DSS, and are likely affected by it to some extent as well (reference: https://doi.org/10.1691/ph.2016.6688).

Minor points

1- It would have been preferable if the authors would have shown the time kinetics of THY1 expression in colon along the course of DSS treatment in mice and afterwards.

2- For apoptosis assay, how could the authors resuspend the cells in 1 microliter binding buffer? I suspect it is a typing error, and needs to be taken care of. Furthermore, didn’t they use any strategy for gating live/dead cells differentially in their flow cytometry data for macrophages?

3- If colonocytes were the target, why did the authors opt for lentivirus injection intravenously?

4- Why didn't the authors opt for showing the intestines from mice groups photographically? It might have been more convincing than putting up a graph.

5- A much better way to represent the data in fig. 3 would have been to gate on the CD11b+ cells, followed by the assessment of CD86 and CD206 simultaneously in them.

6- For cleaved caspase-3 immunoblots, total caspase-3 level needs to be demonstrated as well.

7- Was VEGF levels quantified with or without Golgi-stop/Golgi-plug treatment?

8- For mice experiments, plotting individual data points is always preferable. In addition, it is better to plot SEM rather than SD for showing data corresponding to biological replicates.

9- Did the authors perform normality tests before doing parametric statistical tests?

10- In the cases where authors have claimed “THY1 does so..” and on, should be reframed as “colonocyte-expressed THY1 does so…” or “THY1 on colonocytes does so….”. This will specify the findings.

Reviewer #2: The study by Pengliang Zhang et al claim to identify a novel role of THY 1 in DSS induced colitis. They found out that THY1 promotes inflammatory angiogenesis that exacerbate the disease. The methods and models employed enrich the study and the data gathered collectively reinforces the key hypothesis of the study. The hard work is commendable. However some clarifications are needed.

1.) The study doesn’t appear to be unique and the first of it’s kind as evident from the sentence “In this study, we first revealed the crucial role of the angiogenesis-related target THY1 in the development of acute colitis”. One similar study “The Journal of Immunology, Volume 212, Issue 1,1326_5032, https://doi.org/10.4049/jimmunol.212.supp.1326.5032” published in 2024 had a similar objective and conclusion. Many more can be cited. Hence, it appears that the authors reinforces and substantiate the earlier studies.

2.) Use of a variety of techniques and models often overwhelm the readers. The design could have been much simplified and succinctly presented to make reading and assimilation easier.

3.) Although the authors state the use of AI for improving English, the English still need ample revision.

4.) In the co-culture experiment, choice of human cell lines NCM460 and THP-1 is not accurate. A co-culture of Mice primary intentional epithelial cells and peritoneal macrophages would have been more appropriate to establish and validate the in vitro model

5.) What is the natural ligand for THY1 and are there any inhibitors of THY1 that may have been used alongside or instead of sh-THY1?

The study presents a detailed evaluation of the effect of THY1 in colitis, which needs substantial refinement for enhanced clarity in light of the points raised.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: Yes: Soumyadeep Mukherjee

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Jun 2;21(6):e0350385. doi: 10.1371/journal.pone.0350385.r002

Author response to Decision Letter 1


1 Apr 2026

Dear editor,

Thank you very much for your letter enclosing the academic editor and reviewers’ comments. We appreciate the academic editor and reviewers’ comments for further improving our manuscript PONE-D-26-02176. Those comments are all valuable and very helpful for revising and improving our paper. We have carefully reviewed the comments and have revised the manuscript accordingly, which we hope meet with approval. In the following pages are our point-by-point responses or a rebuttal against each point raised by the academic editor and the reviewers.

We shall look forward to hearing from you at your earliest convenience.

With regards,

Yingjian Zhang

Responses to the academic editor and reviewers’ comments:

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: We have carefully revised our manuscript body formatting according to the PLOS ONE style templates. Manuscript Organization, heading style and File Naming for Figures have been proofread to meets PLOS ONE's style requirements.

2. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Response: We have deleted the "Ethical Considerations" section from our manuscript according to the Journal Requirement.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

Response: The full uncropped Gels and Blots images used in this study have been provided as S3 Fig in Supporting Information.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Response: Checked.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: We have included captions for our Supporting Information files at the end of the manuscript, and updated any in-text citations to match accordingly.

5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Response: Checked.

Reviewer #1: The manuscript entitled “The role and targeting potential analysis of angiogenesis-related target THY1 in DSS-

induced acute colitis in mice” explores the role of THY1 in two aspects of DSS-induced colitis: alterations in colonocyte biology and changes in macrophage phenotypes. While the study apparently focuses on how THY1 regulates the phenotypic alterations of these cells that lead to colitis pathology, there are specific points which are not clear to me in terms of logic, as outlined below.

Major points

1- How well-established is the cell line-based model of IBD (lines 159-161)? Authors need to cite references.

Response: We are very appreciating the reviewer’s comments. According to the reviewer’s suggestion, we have added the relevant reference (https://doi.org/10.5114/ceji.2025.149579) to clarify the maturity of the colitis cell model in our study. According to cited reference, colitis cell models were constructed by treating human normal colonic epithelial cells (FHC) with different concentrations of lipopolysaccharide (LPS) (1, 3, 5, 10, and 15 ng/ml). In our study, normal human intestinal epithelial cell line NCM460 were gradient intervention with different concentrations of dextran sulfate sodium (DSS) (e.g., 0, 0.1, 0.2, 0.5, 1, 2 μg/mL) for 12 hours to establish an IBD cell model. And the expression levels of inflammatory factors including IL-1β, IL-6, TNF-α, and TGF-β in cells were determined to confirm the successful establishment of the model. Our results indicate that an inflammatory bowel disease (IBD) cell model was successfully established based on this cell line.

2- How could the authors guarantee that the lentiviral vector-mediated delivery of the constructs could solely be targeted to colonocytes and not any stromal or immune cells around them? This is particularly important as THY1 expression on stromal cells has a crucial role in colitis pathogenesis (reference: https://doi.org/10.4049/jimmunol.212.supp.1326.5032).

Response: We are very appreciating the reviewer’s comments. We cannot guarantee that the lentiviral vector-mediated delivery of the constructs only targets colonic cells without targeting any surrounding stromal cells or immune cells. However, our study aims to evaluate the role of THY1 in the pathogenesis of DSS-induced colitis in mice, rather than the role of THY1 expression in a single cell type. Therefore, we used lentiviral vector-mediated construct delivery to regulate the expression of THY1 in the colonic tissue of mice, as shown in the results of our Fig 1B.

3- The 2nd point of the results (lines 303-348) only shows that THY1 causes definite changes in macrophage phenotypes parallel to the aggravation of DSS-induced colitis in mice. How could the authors draw a causal inference in the statement “THY1 promotes the pathological process of DSS-induced colitis through inhibiting M2 macrophage polarization?” To establish such causal connection, authors need to experimentally deplete macrophages or alter macrophage phenotypic states under THY1-OE or THY1-silenced conditions, and repeat the same experiments in vivo.

Response: We are very appreciating the reviewer’s comments. We acknowledge that it is necessary to add the experiments suggested by the reviewer to draw the causal inference that "THY1 promotes the pathological process of DSS-induced colitis through inhibiting M2 macrophage polarization." Therefore, we have changed the second point of the results to "THY1 promotes the pathological process of DSS-induced colitis and inhibits M2 macrophage polarization."

4- In the same point, the authors seemingly check several different aspects (cytokines, ROS, angiogenesis markers) related to macrophages. However, there is no definitive proof that the changes in these markers due to THY1 manipulations are solely, or at least majorly, related to their altered output from macrophages in vivo. In addition, why they check so many aspects together without any apparently clear hypothesis is not understandable.

Response: We are very appreciating the reviewer’s comments. The detection of cytokines, reactive oxygen species, and angiogenesis markers is to clarify the effect of THY1 on the pathological process of DSS-induced colitis. First, we found the regulatory effect of THY1 on cytokines, reactive oxygen species, and angiogenesis markers through in vivo experiments. Given that macrophages play an important immunomodulatory role in the pathological process of colitis, in this study, we further elucidated the molecular mechanism from the perspective of macrophage immunomodulation through an in vitro co-culture system of intestinal epithelial cells and macrophages.

5- Again, in the coming sections, authors assess colonocyte apoptosis and angiogenesis marker levels without any clear connection to the previous sections. The entire story looks like an ensemble of experiments without any proper logical link among them.

Response: We are very appreciating the reviewer’s comments. This study aimed to explored and demonstrated the potential role of THY1 in the pathological mechanism of IBD from multiple perspectives based on DSS-induced acute colitis in mice and colonocytes models. Existing studies have shown that the impairment of the intestinal epithelial cell barrier function caused by colonic cell apoptosis is a key initiating factor in the pathogenesis of IBD, and abnormal angiogenesis can provide nutritional support for the infiltration of inflammatory cells and exacerbate the inflammatory response. Therefore, on the basis of revealing the potential role of THY1 in the pathological mechanism of IBD from the perspective of macrophage immunomodulation, we further revealed the role of THY1 in the pathogenesis of IBD from the perspectives of colonocyte apoptosis and abnormal angiogenesis, aiming to provide theoretical support for the development of THY1-targeted IBD treatment strategies. We acknowledge that the proper logical link among them was not shown in this study. However, this study has completely revealed the role and targeting potential of angiogenesis-related target THY1 in DSS-induced acute colitis in mice. Moreover, we have pointed out the limitations of this study in the discussion section.

6- Although the authors check multiple phenotypic effects of THY1 manipulations on colonocytes, how each of them affects colitis has not been checked. So the entire set of findings by large stays correlative.

Response: We are very appreciating the reviewer’s comments. Regarding the limitations of this study pointed out by the reviewer, it should be noted that in this study, we aimed to explored and demonstrated the potential role of THY1 in the pathological mechanism of IBD from multiple perspectives based on DSS-induced acute colitis in mice and colonocytes models, providing theoretical support for the development of THY1-targeted IBD treatment strategies. In addition, in the discussion section, we also pointed out the limitations of this study, including that the molecular mechanism by which THY1 mediates angiogenesis and affects colitis needs to be fully elucidated.

7- Why do the authors check ROS-related phenotypes (ROS, MDA, GSH etc) in cell supernatants? It would have been more physiologically relevant if they had done the experiment with cell homogenates/lysates.

Response: We are very appreciating the reviewer’s comments. We already have done the experiment with cell homogenates/lysates, which was shown as S3 in Supporting Information files. According to the review’s comments, we have replaced the detection results in the cell supernatant with those in the cell homogenate/lysate, as revised in Fig 2B.

8- None of the experiments involve DSS-conditioning of the THP-1 cells, and only involves co-culturing them with colonocytes of different phenotypes. This violates the physiology of colitis, where macrophages also encounter DSS, and are likely affected by it to some extent as well (reference: ).

Response: We are very appreciating the reviewer’s comments. In our co-culture system of intestinal epithelial cells and macrophages, we aimed to investigate the immunomodulatory role of macrophages in the pathological process of colitis regulated by THY1. Therefore, the DSS-conditioning of the THP-1 cells group was not necessary.

Minor points

1- It would have been preferable if the authors would have shown the time kinetics of THY1 expression in colon along the course of DSS treatment in mice and afterwards.

Response: We are very appreciating the reviewer’s comments. In this study, we used lentiviral vector-mediated construct delivery to regulate the expression of THY1 in the colonic tissue of mice. Through end-point mode evaluation, we further explored the potential role of THY1 in the pathological mechanism of DSS-induced colitis. It is worth noting that the temporal dynamics of THY1 expression in colonic tissues were not the core presentation content of this study, so they were not presented in detail.

2- For apoptosis assay, how could the authors resuspend the cells in 1 microliter binding buffer? I suspect it is a typing error, and needs to be taken care of. Furthermore, didn’t they use any strategy for gating live/dead cells differentially in their flow cytometry data for macrophages?

Response: We are very appreciating the reviewer’s comments. By examining the data from our apoptosis assay, we found that the cells were resuspended in 300 microliters of binding buffer. Therefore, we have revised the error in text as follows: “Cells were harvested, rinsed with PBS, and resuspended in 300 microliters of Annexin V binding buffer to achieve a single-cell suspension.” For macrophage immunophenotyping analysis, we adopted a gating strategy to select live CD11b+ macrophages. Specifically, we first excluded debris and doublet cells using forward scatter (FSC)/side scatter (SSC) parameters, then selected live CD11b+ monocytes/macrophages. We have added the following modification to the text: “The gating strategy adopted a step-by-step approach: First, use the forward scatter (FSC)/side scatter (SSC) parameters to exclude debris and doublet cells, and then select live CD11b+ monocytes/macrophages.”

3- If colonocytes were the target, why did the authors opt for lentivirus injection intravenously?

Response: We are very appreciating the reviewer’s comments. Our study aims to evaluate the role of THY1 in the pathogenesis of DSS-induced colitis in mice, rather than the role of THY1 expression in a single cell type. Therefore, we used lentiviral vector-mediated construct delivery to regulate the expression of THY1 in the colonic tissue of mice, as shown in the results of our Fig 1B.

4- Why didn't the authors opt for showing the intestines from mice groups photographically? It might have been more convincing than putting up a graph.

Response: We are very appreciating the reviewer’s comments. Since all groups of colons were not arranged and photographed during the mouse dissection, we did not visually present pictures of intestinal tissues. However, we have taken comparative photos of the THY1 overexpression group and the Sham group, as shown below. We guarantee that all data is real and reliable, and no photo display is required.

5- A much better way to represent the data in fig. 3 would have been to gate on the CD11b+ cells, followed by the assessment of CD86 and CD206 simultaneously in them.

Response: We are very appreciating the reviewer’s comments. In this study, we have adopted a gating strategy to select live CD11b+ macrophages for macrophage immunophenotyping analysis. According to the review’s second minor point, we have added the following modification to the method section: “The gating strategy adopted a step-by-step approach: First, use the forward scatter (FSC)/side scatter (SSC) parameters to exclude debris and doublet cells, and then select live CD11b+ monocytes/macrophages.” In addition, given the large number of groups included in this study, incorporating the gating data into the current Fig 3 would result in an excessive number of panels within the overall data graph. This would compromise the clarity and effectiveness of the presentation. Based on this, we believe that there is no need to add additional gating data at present to ensure the simplicity of the chart and the effectiveness of information transmission.

6- For cleaved cas

Attachment

Submitted filename: Response to reviewers.docx

pone.0350385.s006.docx (103.4KB, docx)

Decision Letter 1

Subhasis Barik

13 May 2026

The role and targeting potential analysis of angiogenesis-related target THY1 in DSS-induced acute colitis in mice

PONE-D-26-02176R1

Dear Dr. Zhang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Subhasis Barik

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: All comments from the previous round have been addressed. I recommend the manuscript for acceptance in its current form.

Reviewer #2: The revised manuscript is fair enough for acceptance. The authors have responded to the reviewer comments with clarity.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Subhasis Barik

PONE-D-26-02176R1

PLOS One

Dear Dr. Zhang,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Subhasis Barik

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Evaluation of the effectiveness of cell model establishment.

    The expression levels of inflammatory factors including IL-1β, IL-6, TNF-α, and TGF-β in NCM460 cells (A) and its supernatant (B) were detected by ELISA. NCM460 cells were gradient intervention with different concentrations of DSS (e.g., 0, 0.1, 0.2, 0.5, 1, 2 μg/mL) for 12 hours. A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

    (TIF)

    pone.0350385.s001.tif (1.3MB, tif)
    S2 Fig. THY1 promotes the pathological process of DSS-induced colitis.

    The expression levels of inflammatory factors (IL-1β, TNF-α and TGF-β), oxidative stress-related molecules (ROS, MDA and GSH) and angiogenesis-related stimulatory factors (HIF-1α and VEGF) in mouse blood serum samples of different treatment groups were detected by enzyme-linked immunosorbent assay (ELISA). A minimum of three separate experiments were carried out and the data presented are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

    (TIF)

    pone.0350385.s002.tif (4.2MB, tif)
    S3 Fig. The full uncropped Gels and Blots images used in this study.

    (PDF)

    pone.0350385.s003.pdf (284.7KB, pdf)
    S4 Fig. Original data sets for Figures in this study.

    (ZIP)

    pone.0350385.s004.zip (28.9MB, zip)
    Attachment

    Submitted filename: Response to reviewers.docx

    pone.0350385.s006.docx (103.4KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES